Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

CNBC reports Eli Lilly is acquiring AtaiBeckley, a psychedelics maker, for two point eight billion dollars to gain access to experimental treatments based on DMT and MDMA. The deal reflects growing pharmaceutical interest in psychedelic-assisted therapies as research into their potential accelerates.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton